Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
Outlook Therapeutics, Inc. entered into Sales Agreement with BTIG, LLC valued at aggregate offering price of up to $100,000,000 (effective 2023-05-16).
- Action
- entry
- Agreement
- atm program
- Counterparty
- BTIG, LLC
- Value
- aggregate offering price of up to $100,000,000
- Effective
- 2023-05-16
Exact text from the filing
On May 16, 2023, Outlook Therapeutics, Inc. (the “Company”) entered into an at-the-market-sales agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share (“Common Stock”), from time to time through BTIG as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the “Shares”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
Outlook Therapeutics, Inc. terminated Prior Sales Agreement with H.C. Wainwright & Co. valued at at-the-market offering agreement dated as of March 26, 2021, with aggregate offering price of up to (effective 2023-05-15).
- Action
- termination
- Agreement
- atm program
- Counterparty
- H.C. Wainwright & Co.
- Value
- at-the-market offering agreement dated as of March 26, 2021, with aggregate offering price of up to
- Effective
- 2023-05-15
Exact text from the filing
In connection with entering into the Sales Agreement, the Company terminated, effective May 15, 2023, its at-the-market offering agreement, dated as of March 26, 2021 (the “Prior Sales Agreement”) with H.C. Wainwright & Co. with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $40,000,000 (the “Prior ATM Program”).
View on SEC.gov